nodes	percent_of_prediction	percent_of_DWPC	metapath
Haloperidol—Fluspirilene—Ezetimibe—atherosclerosis	0.327	1	CrCrCtD
Haloperidol—HRH1—atherosclerosis	0.243	1	CbGaD
Haloperidol—CYP3A7-CYP3A51P—Simvastatin—atherosclerosis	0.0174	0.0615	CbGbCtD
Haloperidol—CYP3A7—Simvastatin—atherosclerosis	0.0174	0.0615	CbGbCtD
Haloperidol—CYP3A7—Lovastatin—atherosclerosis	0.0171	0.0602	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Lovastatin—atherosclerosis	0.0171	0.0602	CbGbCtD
Haloperidol—CYP3A5—Rosuvastatin—atherosclerosis	0.0141	0.0496	CbGbCtD
Haloperidol—CYP3A5—Simvastatin—atherosclerosis	0.0131	0.0461	CbGbCtD
Haloperidol—CYP3A5—Lovastatin—atherosclerosis	0.0128	0.0451	CbGbCtD
Haloperidol—CYP3A5—Pravastatin—atherosclerosis	0.0128	0.0451	CbGbCtD
Haloperidol—CYP2C19—Rosuvastatin—atherosclerosis	0.0113	0.04	CbGbCtD
Haloperidol—CYP2C19—Simvastatin—atherosclerosis	0.0105	0.0372	CbGbCtD
Haloperidol—CYP2C19—Lovastatin—atherosclerosis	0.0103	0.0364	CbGbCtD
Haloperidol—CYP2D6—Niacin—atherosclerosis	0.0101	0.0358	CbGbCtD
Haloperidol—CYP2C9—Rosuvastatin—atherosclerosis	0.00943	0.0333	CbGbCtD
Haloperidol—ABCB1—Ezetimibe—atherosclerosis	0.00915	0.0323	CbGbCtD
Haloperidol—CYP2C9—Simvastatin—atherosclerosis	0.00877	0.0309	CbGbCtD
Haloperidol—CYP2C9—Lovastatin—atherosclerosis	0.00858	0.0303	CbGbCtD
Haloperidol—CYP2C9—Pravastatin—atherosclerosis	0.00858	0.0303	CbGbCtD
Haloperidol—ABCB1—Simvastatin—atherosclerosis	0.00851	0.03	CbGbCtD
Haloperidol—ABCB1—Pravastatin—atherosclerosis	0.00832	0.0294	CbGbCtD
Haloperidol—ABCB1—Lovastatin—atherosclerosis	0.00832	0.0294	CbGbCtD
Haloperidol—CYP2D6—Simvastatin—atherosclerosis	0.00801	0.0283	CbGbCtD
Haloperidol—CYP2D6—Pravastatin—atherosclerosis	0.00784	0.0277	CbGbCtD
Haloperidol—CYP2D6—Lovastatin—atherosclerosis	0.00784	0.0277	CbGbCtD
Haloperidol—CYP3A4—Rosuvastatin—atherosclerosis	0.00548	0.0193	CbGbCtD
Haloperidol—CYP3A4—Ezetimibe—atherosclerosis	0.00548	0.0193	CbGbCtD
Haloperidol—CYP3A4—Simvastatin—atherosclerosis	0.0051	0.018	CbGbCtD
Haloperidol—CYP3A4—Lovastatin—atherosclerosis	0.00499	0.0176	CbGbCtD
Haloperidol—CYP3A4—Pravastatin—atherosclerosis	0.00499	0.0176	CbGbCtD
Haloperidol—HTR2A—arteriole—atherosclerosis	0.00149	0.102	CbGeAlD
Haloperidol—Loss of libido—Pravastatin—atherosclerosis	0.00106	0.0163	CcSEcCtD
Haloperidol—Pregnancy—Lovastatin—atherosclerosis	0.00102	0.0157	CcSEcCtD
Haloperidol—Sexual dysfunction—Simvastatin—atherosclerosis	0.000968	0.0148	CcSEcCtD
Haloperidol—Pregnancy—Simvastatin—atherosclerosis	0.000956	0.0146	CcSEcCtD
Haloperidol—Bepotastine—HRH1—atherosclerosis	0.000935	0.36	CrCbGaD
Haloperidol—HTR2A—vein—atherosclerosis	0.00089	0.0611	CbGeAlD
Haloperidol—Sexual dysfunction—Pravastatin—atherosclerosis	0.000875	0.0134	CcSEcCtD
Haloperidol—Libido increased—Niacin—atherosclerosis	0.000819	0.0125	CcSEcCtD
Haloperidol—Laryngeal oedema—Niacin—atherosclerosis	0.000776	0.0119	CcSEcCtD
Haloperidol—HTR1B—artery—atherosclerosis	0.000754	0.0517	CbGeAlD
Haloperidol—Cetirizine—HRH1—atherosclerosis	0.000744	0.286	CrCbGaD
Haloperidol—Hypokinesia—Niacin—atherosclerosis	0.000738	0.0113	CcSEcCtD
Haloperidol—HTR1D—artery—atherosclerosis	0.00073	0.0501	CbGeAlD
Haloperidol—Laryngospasm—Niacin—atherosclerosis	0.000667	0.0102	CcSEcCtD
Haloperidol—Cholestasis—Niacin—atherosclerosis	0.000656	0.01	CcSEcCtD
Haloperidol—Endocrine disorder—Simvastatin—atherosclerosis	0.000654	0.01	CcSEcCtD
Haloperidol—Gynaecomastia—Rosuvastatin—atherosclerosis	0.000612	0.00938	CcSEcCtD
Haloperidol—Cataract—Lovastatin—atherosclerosis	0.000609	0.00933	CcSEcCtD
Haloperidol—Hypertonia—Rosuvastatin—atherosclerosis	0.0006	0.00919	CcSEcCtD
Haloperidol—HTR2A—hindlimb—atherosclerosis	0.000591	0.0406	CbGeAlD
Haloperidol—HTR1B—blood vessel—atherosclerosis	0.000587	0.0403	CbGeAlD
Haloperidol—Breast pain—Niacin—atherosclerosis	0.000571	0.00875	CcSEcCtD
Haloperidol—Cataract—Simvastatin—atherosclerosis	0.00057	0.00873	CcSEcCtD
Haloperidol—HTR1D—blood vessel—atherosclerosis	0.000568	0.039	CbGeAlD
Haloperidol—EBP—liver—atherosclerosis	0.000542	0.0372	CbGeAlD
Haloperidol—Gynaecomastia—Lovastatin—atherosclerosis	0.000519	0.00795	CcSEcCtD
Haloperidol—Cataract—Pravastatin—atherosclerosis	0.000515	0.00789	CcSEcCtD
Haloperidol—Muscle twitching—Niacin—atherosclerosis	0.000507	0.00777	CcSEcCtD
Haloperidol—HTR2A—appendage—atherosclerosis	0.000507	0.0348	CbGeAlD
Haloperidol—Sertindole—HRH1—atherosclerosis	0.000507	0.195	CrCbGaD
Haloperidol—Gynaecomastia—Simvastatin—atherosclerosis	0.000485	0.00744	CcSEcCtD
Haloperidol—Hepatic function abnormal—Lovastatin—atherosclerosis	0.000482	0.00738	CcSEcCtD
Haloperidol—Photosensitivity—Lovastatin—atherosclerosis	0.00048	0.00734	CcSEcCtD
Haloperidol—Photosensitivity—Ezetimibe—atherosclerosis	0.00047	0.0072	CcSEcCtD
Haloperidol—Hepatic function abnormal—Simvastatin—atherosclerosis	0.000451	0.0069	CcSEcCtD
Haloperidol—Breast disorder—Rosuvastatin—atherosclerosis	0.000449	0.00688	CcSEcCtD
Haloperidol—Photosensitivity—Simvastatin—atherosclerosis	0.000449	0.00687	CcSEcCtD
Haloperidol—Gynaecomastia—Pravastatin—atherosclerosis	0.000439	0.00672	CcSEcCtD
Haloperidol—Hypertonia—Niacin—atherosclerosis	0.000437	0.00669	CcSEcCtD
Haloperidol—Hepatic function abnormal—Niacin—atherosclerosis	0.000414	0.00634	CcSEcCtD
Haloperidol—Fluspirilene—HRH1—atherosclerosis	0.000413	0.159	CrCbGaD
Haloperidol—Hepatic function abnormal—Pravastatin—atherosclerosis	0.000407	0.00624	CcSEcCtD
Haloperidol—Photosensitivity—Pravastatin—atherosclerosis	0.000405	0.00621	CcSEcCtD
Haloperidol—CBR1—cardiovascular system—atherosclerosis	0.0004	0.0274	CbGeAlD
Haloperidol—Depression—Rosuvastatin—atherosclerosis	0.000382	0.00585	CcSEcCtD
Haloperidol—Liver function test abnormal—Ezetimibe—atherosclerosis	0.000381	0.00584	CcSEcCtD
Haloperidol—H1F0—connective tissue—atherosclerosis	0.000376	0.0258	CbGeAlD
Haloperidol—Jaundice—Rosuvastatin—atherosclerosis	0.000373	0.00572	CcSEcCtD
Haloperidol—Breast disorder—Ezetimibe—atherosclerosis	0.000373	0.00572	CcSEcCtD
Haloperidol—HTR2A—artery—atherosclerosis	0.000362	0.0249	CbGeAlD
Haloperidol—Hepatobiliary disease—Rosuvastatin—atherosclerosis	0.000362	0.00555	CcSEcCtD
Haloperidol—Disturbance in sexual arousal—Niacin—atherosclerosis	0.000359	0.0055	CcSEcCtD
Haloperidol—CBR1—adipose tissue—atherosclerosis	0.000352	0.0242	CbGeAlD
Haloperidol—Face oedema—Niacin—atherosclerosis	0.000349	0.00535	CcSEcCtD
Haloperidol—Urinary retention—Niacin—atherosclerosis	0.000344	0.00527	CcSEcCtD
Haloperidol—Hepatitis—Rosuvastatin—atherosclerosis	0.000344	0.00526	CcSEcCtD
Haloperidol—Erectile dysfunction—Lovastatin—atherosclerosis	0.000335	0.00513	CcSEcCtD
Haloperidol—Liver function test abnormal—Niacin—atherosclerosis	0.000334	0.00511	CcSEcCtD
Haloperidol—Photosensitivity reaction—Lovastatin—atherosclerosis	0.000332	0.00509	CcSEcCtD
Haloperidol—Orthostatic hypotension—Niacin—atherosclerosis	0.00033	0.00506	CcSEcCtD
Haloperidol—Erectile dysfunction—Ezetimibe—atherosclerosis	0.000329	0.00504	CcSEcCtD
Haloperidol—Liver function test abnormal—Pravastatin—atherosclerosis	0.000329	0.00504	CcSEcCtD
Haloperidol—UGT1A9—liver—atherosclerosis	0.000328	0.0225	CbGeAlD
Haloperidol—H1F0—cardiovascular system—atherosclerosis	0.000327	0.0225	CbGeAlD
Haloperidol—Photosensitivity reaction—Ezetimibe—atherosclerosis	0.000326	0.00499	CcSEcCtD
Haloperidol—Erectile dysfunction—Simvastatin—atherosclerosis	0.000313	0.0048	CcSEcCtD
Haloperidol—Dysphagia—Niacin—atherosclerosis	0.000313	0.00479	CcSEcCtD
Haloperidol—Photosensitivity reaction—Simvastatin—atherosclerosis	0.000311	0.00476	CcSEcCtD
Haloperidol—Jaundice—Ezetimibe—atherosclerosis	0.00031	0.00475	CcSEcCtD
Haloperidol—HTR2A—endothelium—atherosclerosis	0.000306	0.021	CbGeAlD
Haloperidol—Depression—Simvastatin—atherosclerosis	0.000303	0.00464	CcSEcCtD
Haloperidol—Mental disorder—Rosuvastatin—atherosclerosis	0.000301	0.00461	CcSEcCtD
Haloperidol—Hepatobiliary disease—Ezetimibe—atherosclerosis	0.000301	0.00461	CcSEcCtD
Haloperidol—Sweating increased—Pravastatin—atherosclerosis	0.0003	0.00459	CcSEcCtD
Haloperidol—Jaundice—Simvastatin—atherosclerosis	0.000296	0.00453	CcSEcCtD
Haloperidol—HTR1D—connective tissue—atherosclerosis	0.000291	0.02	CbGeAlD
Haloperidol—Hepatitis—Lovastatin—atherosclerosis	0.000291	0.00446	CcSEcCtD
Haloperidol—H1F0—adipose tissue—atherosclerosis	0.000289	0.0198	CbGeAlD
Haloperidol—Erectile dysfunction—Niacin—atherosclerosis	0.000288	0.00441	CcSEcCtD
Haloperidol—Hepatitis—Ezetimibe—atherosclerosis	0.000286	0.00438	CcSEcCtD
Haloperidol—Erectile dysfunction—Pravastatin—atherosclerosis	0.000283	0.00434	CcSEcCtD
Haloperidol—HTR2A—blood vessel—atherosclerosis	0.000282	0.0194	CbGeAlD
Haloperidol—Photosensitivity reaction—Pravastatin—atherosclerosis	0.000281	0.0043	CcSEcCtD
Haloperidol—Connective tissue disorder—Ezetimibe—atherosclerosis	0.000281	0.0043	CcSEcCtD
Haloperidol—Weight increased—Pravastatin—atherosclerosis	0.00028	0.00429	CcSEcCtD
Haloperidol—Weight decreased—Pravastatin—atherosclerosis	0.000278	0.00426	CcSEcCtD
Haloperidol—Depression—Pravastatin—atherosclerosis	0.000274	0.00419	CcSEcCtD
Haloperidol—CYP3A7—liver—atherosclerosis	0.000273	0.0187	CbGeAlD
Haloperidol—Hepatitis—Simvastatin—atherosclerosis	0.000272	0.00417	CcSEcCtD
Haloperidol—Jaundice—Niacin—atherosclerosis	0.000272	0.00416	CcSEcCtD
Haloperidol—Jaundice—Pravastatin—atherosclerosis	0.000267	0.0041	CcSEcCtD
Haloperidol—HTR1B—cardiovascular system—atherosclerosis	0.000262	0.018	CbGeAlD
Haloperidol—Angiopathy—Ezetimibe—atherosclerosis	0.000259	0.00397	CcSEcCtD
Haloperidol—Immune system disorder—Ezetimibe—atherosclerosis	0.000258	0.00395	CcSEcCtD
Haloperidol—Mediastinal disorder—Ezetimibe—atherosclerosis	0.000257	0.00394	CcSEcCtD
Haloperidol—Alopecia—Lovastatin—atherosclerosis	0.000257	0.00394	CcSEcCtD
Haloperidol—HTR1D—cardiovascular system—atherosclerosis	0.000254	0.0174	CbGeAlD
Haloperidol—Alopecia—Ezetimibe—atherosclerosis	0.000252	0.00387	CcSEcCtD
Haloperidol—Mental disorder—Ezetimibe—atherosclerosis	0.00025	0.00383	CcSEcCtD
Haloperidol—Hepatitis—Niacin—atherosclerosis	0.00025	0.00383	CcSEcCtD
Haloperidol—Malnutrition—Ezetimibe—atherosclerosis	0.000249	0.00381	CcSEcCtD
Haloperidol—CBR1—liver—atherosclerosis	0.000247	0.017	CbGeAlD
Haloperidol—Hepatitis—Pravastatin—atherosclerosis	0.000246	0.00377	CcSEcCtD
Haloperidol—Confusional state—Rosuvastatin—atherosclerosis	0.000246	0.00377	CcSEcCtD
Haloperidol—Muscle spasms—Lovastatin—atherosclerosis	0.000244	0.00373	CcSEcCtD
Haloperidol—Visual impairment—Niacin—atherosclerosis	0.000241	0.00369	CcSEcCtD
Haloperidol—Alopecia—Simvastatin—atherosclerosis	0.000241	0.00369	CcSEcCtD
Haloperidol—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000239	0.00367	CcSEcCtD
Haloperidol—Muscle spasms—Ezetimibe—atherosclerosis	0.000239	0.00366	CcSEcCtD
Haloperidol—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000239	0.00366	CcSEcCtD
Haloperidol—Vision blurred—Lovastatin—atherosclerosis	0.000239	0.00366	CcSEcCtD
Haloperidol—Mental disorder—Simvastatin—atherosclerosis	0.000239	0.00366	CcSEcCtD
Haloperidol—Tremor—Lovastatin—atherosclerosis	0.000238	0.00364	CcSEcCtD
Haloperidol—Visual impairment—Pravastatin—atherosclerosis	0.000237	0.00364	CcSEcCtD
Haloperidol—HTR2B—cardiovascular system—atherosclerosis	0.000236	0.0162	CbGeAlD
Haloperidol—Eye disorder—Niacin—atherosclerosis	0.000234	0.00358	CcSEcCtD
Haloperidol—CYP3A7-CYP3A51P—liver—atherosclerosis	0.000232	0.0159	CbGeAlD
Haloperidol—Anaemia—Ezetimibe—atherosclerosis	0.00023	0.00352	CcSEcCtD
Haloperidol—Cardiac disorder—Pravastatin—atherosclerosis	0.000229	0.0035	CcSEcCtD
Haloperidol—Muscle spasms—Simvastatin—atherosclerosis	0.000228	0.00349	CcSEcCtD
Haloperidol—Vertigo—Lovastatin—atherosclerosis	0.000228	0.00349	CcSEcCtD
Haloperidol—Angiopathy—Niacin—atherosclerosis	0.000227	0.00348	CcSEcCtD
Haloperidol—Leukopenia—Lovastatin—atherosclerosis	0.000227	0.00348	CcSEcCtD
Haloperidol—Vision blurred—Simvastatin—atherosclerosis	0.000224	0.00342	CcSEcCtD
Haloperidol—Tremor—Simvastatin—atherosclerosis	0.000222	0.0034	CcSEcCtD
Haloperidol—Alopecia—Niacin—atherosclerosis	0.000221	0.00339	CcSEcCtD
Haloperidol—Insomnia—Rosuvastatin—atherosclerosis	0.000221	0.00338	CcSEcCtD
Haloperidol—Anaemia—Simvastatin—atherosclerosis	0.000219	0.00336	CcSEcCtD
Haloperidol—Malnutrition—Niacin—atherosclerosis	0.000218	0.00334	CcSEcCtD
Haloperidol—Alopecia—Pravastatin—atherosclerosis	0.000218	0.00333	CcSEcCtD
Haloperidol—Anxiety—Lovastatin—atherosclerosis	0.000215	0.0033	CcSEcCtD
Haloperidol—Dyspepsia—Rosuvastatin—atherosclerosis	0.000215	0.00329	CcSEcCtD
Haloperidol—Hypertension—Ezetimibe—atherosclerosis	0.000215	0.00329	CcSEcCtD
Haloperidol—Vertigo—Simvastatin—atherosclerosis	0.000213	0.00326	CcSEcCtD
Haloperidol—Leukopenia—Simvastatin—atherosclerosis	0.000212	0.00325	CcSEcCtD
Haloperidol—Dry mouth—Lovastatin—atherosclerosis	0.000211	0.00323	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.00021	0.00322	CcSEcCtD
Haloperidol—Muscle spasms—Niacin—atherosclerosis	0.000209	0.00321	CcSEcCtD
Haloperidol—Constipation—Rosuvastatin—atherosclerosis	0.000209	0.0032	CcSEcCtD
Haloperidol—Confusional state—Lovastatin—atherosclerosis	0.000209	0.0032	CcSEcCtD
Haloperidol—SIGMAR1—adipose tissue—atherosclerosis	0.000208	0.0143	CbGeAlD
Haloperidol—HTR2B—adipose tissue—atherosclerosis	0.000208	0.0143	CbGeAlD
Haloperidol—Dry mouth—Ezetimibe—atherosclerosis	0.000207	0.00317	CcSEcCtD
Haloperidol—Anaphylactic shock—Lovastatin—atherosclerosis	0.000207	0.00317	CcSEcCtD
Haloperidol—Muscle spasms—Pravastatin—atherosclerosis	0.000206	0.00316	CcSEcCtD
Haloperidol—Vision blurred—Niacin—atherosclerosis	0.000205	0.00314	CcSEcCtD
Haloperidol—Confusional state—Ezetimibe—atherosclerosis	0.000205	0.00313	CcSEcCtD
Haloperidol—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000203	0.00311	CcSEcCtD
Haloperidol—Thrombocytopenia—Lovastatin—atherosclerosis	0.000203	0.0031	CcSEcCtD
Haloperidol—H1F0—liver—atherosclerosis	0.000202	0.0139	CbGeAlD
Haloperidol—Vision blurred—Pravastatin—atherosclerosis	0.000202	0.0031	CcSEcCtD
Haloperidol—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000201	0.00308	CcSEcCtD
Haloperidol—Anxiety—Simvastatin—atherosclerosis	0.000201	0.00308	CcSEcCtD
Haloperidol—Tremor—Pravastatin—atherosclerosis	0.000201	0.00308	CcSEcCtD
Haloperidol—Nervous system disorder—Ezetimibe—atherosclerosis	0.000199	0.00305	CcSEcCtD
Haloperidol—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000199	0.00304	CcSEcCtD
Haloperidol—Anaemia—Pravastatin—atherosclerosis	0.000198	0.00304	CcSEcCtD
Haloperidol—Anorexia—Lovastatin—atherosclerosis	0.000197	0.00302	CcSEcCtD
Haloperidol—Skin disorder—Ezetimibe—atherosclerosis	0.000197	0.00302	CcSEcCtD
Haloperidol—Vertigo—Niacin—atherosclerosis	0.000196	0.003	CcSEcCtD
Haloperidol—Confusional state—Simvastatin—atherosclerosis	0.000195	0.00299	CcSEcCtD
Haloperidol—Leukopenia—Niacin—atherosclerosis	0.000195	0.00299	CcSEcCtD
Haloperidol—Urticaria—Rosuvastatin—atherosclerosis	0.000194	0.00297	CcSEcCtD
Haloperidol—Anaphylactic shock—Simvastatin—atherosclerosis	0.000194	0.00296	CcSEcCtD
Haloperidol—Oedema—Simvastatin—atherosclerosis	0.000194	0.00296	CcSEcCtD
Haloperidol—Vertigo—Pravastatin—atherosclerosis	0.000193	0.00295	CcSEcCtD
Haloperidol—Leukopenia—Pravastatin—atherosclerosis	0.000192	0.00294	CcSEcCtD
Haloperidol—Thrombocytopenia—Simvastatin—atherosclerosis	0.00019	0.0029	CcSEcCtD
Haloperidol—KCNH2—cardiovascular system—atherosclerosis	0.000188	0.0129	CbGeAlD
Haloperidol—Insomnia—Lovastatin—atherosclerosis	0.000187	0.00287	CcSEcCtD
Haloperidol—Hypertension—Pravastatin—atherosclerosis	0.000185	0.00284	CcSEcCtD
Haloperidol—ABCB1—blood vessel—atherosclerosis	0.000185	0.0127	CbGeAlD
Haloperidol—Anorexia—Simvastatin—atherosclerosis	0.000185	0.00283	CcSEcCtD
Haloperidol—Dyspnoea—Lovastatin—atherosclerosis	0.000184	0.00283	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000184	0.00282	CcSEcCtD
Haloperidol—Insomnia—Ezetimibe—atherosclerosis	0.000184	0.00281	CcSEcCtD
Haloperidol—Dyspepsia—Lovastatin—atherosclerosis	0.000182	0.00279	CcSEcCtD
Haloperidol—Anxiety—Pravastatin—atherosclerosis	0.000182	0.00279	CcSEcCtD
Haloperidol—Dry mouth—Niacin—atherosclerosis	0.000181	0.00278	CcSEcCtD
Haloperidol—Dyspnoea—Ezetimibe—atherosclerosis	0.000181	0.00277	CcSEcCtD
Haloperidol—Hypersensitivity—Rosuvastatin—atherosclerosis	0.00018	0.00276	CcSEcCtD
Haloperidol—Decreased appetite—Lovastatin—atherosclerosis	0.00018	0.00276	CcSEcCtD
Haloperidol—Dyspepsia—Ezetimibe—atherosclerosis	0.000179	0.00274	CcSEcCtD
Haloperidol—Oedema—Niacin—atherosclerosis	0.000178	0.00272	CcSEcCtD
Haloperidol—Anaphylactic shock—Niacin—atherosclerosis	0.000178	0.00272	CcSEcCtD
Haloperidol—Constipation—Lovastatin—atherosclerosis	0.000177	0.00271	CcSEcCtD
Haloperidol—Confusional state—Pravastatin—atherosclerosis	0.000176	0.0027	CcSEcCtD
Haloperidol—Decreased appetite—Ezetimibe—atherosclerosis	0.000176	0.0027	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000175	0.00268	CcSEcCtD
Haloperidol—Insomnia—Simvastatin—atherosclerosis	0.000175	0.00268	CcSEcCtD
Haloperidol—Oedema—Pravastatin—atherosclerosis	0.000175	0.00268	CcSEcCtD
Haloperidol—Anaphylactic shock—Pravastatin—atherosclerosis	0.000175	0.00268	CcSEcCtD
Haloperidol—Constipation—Ezetimibe—atherosclerosis	0.000174	0.00266	CcSEcCtD
Haloperidol—Tachycardia—Niacin—atherosclerosis	0.000173	0.00266	CcSEcCtD
Haloperidol—HRH1—connective tissue—atherosclerosis	0.000173	0.0119	CbGeAlD
Haloperidol—Pruritus—Rosuvastatin—atherosclerosis	0.000173	0.00265	CcSEcCtD
Haloperidol—Skin disorder—Niacin—atherosclerosis	0.000173	0.00264	CcSEcCtD
Haloperidol—Dyspnoea—Simvastatin—atherosclerosis	0.000173	0.00264	CcSEcCtD
Haloperidol—Hyperhidrosis—Niacin—atherosclerosis	0.000172	0.00263	CcSEcCtD
Haloperidol—Thrombocytopenia—Pravastatin—atherosclerosis	0.000171	0.00262	CcSEcCtD
Haloperidol—Feeling abnormal—Lovastatin—atherosclerosis	0.000171	0.00261	CcSEcCtD
Haloperidol—Dyspepsia—Simvastatin—atherosclerosis	0.00017	0.00261	CcSEcCtD
Haloperidol—Anorexia—Niacin—atherosclerosis	0.000169	0.0026	CcSEcCtD
Haloperidol—Hyperhidrosis—Pravastatin—atherosclerosis	0.000169	0.00259	CcSEcCtD
Haloperidol—Decreased appetite—Simvastatin—atherosclerosis	0.000168	0.00258	CcSEcCtD
Haloperidol—Feeling abnormal—Ezetimibe—atherosclerosis	0.000167	0.00256	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000167	0.00256	CcSEcCtD
Haloperidol—Diarrhoea—Rosuvastatin—atherosclerosis	0.000167	0.00256	CcSEcCtD
Haloperidol—Anorexia—Pravastatin—atherosclerosis	0.000167	0.00256	CcSEcCtD
Haloperidol—Hypotension—Niacin—atherosclerosis	0.000166	0.00254	CcSEcCtD
Haloperidol—Constipation—Simvastatin—atherosclerosis	0.000166	0.00254	CcSEcCtD
Haloperidol—Urticaria—Lovastatin—atherosclerosis	0.000164	0.00252	CcSEcCtD
Haloperidol—Body temperature increased—Lovastatin—atherosclerosis	0.000164	0.00251	CcSEcCtD
Haloperidol—Dizziness—Rosuvastatin—atherosclerosis	0.000161	0.00247	CcSEcCtD
Haloperidol—Urticaria—Ezetimibe—atherosclerosis	0.000161	0.00247	CcSEcCtD
Haloperidol—Insomnia—Niacin—atherosclerosis	0.000161	0.00246	CcSEcCtD
Haloperidol—Body temperature increased—Ezetimibe—atherosclerosis	0.00016	0.00246	CcSEcCtD
Haloperidol—Feeling abnormal—Simvastatin—atherosclerosis	0.00016	0.00244	CcSEcCtD
Haloperidol—Dyspnoea—Niacin—atherosclerosis	0.000158	0.00243	CcSEcCtD
Haloperidol—Insomnia—Pravastatin—atherosclerosis	0.000158	0.00242	CcSEcCtD
Haloperidol—Somnolence—Niacin—atherosclerosis	0.000158	0.00242	CcSEcCtD
Haloperidol—Dyspepsia—Niacin—atherosclerosis	0.000156	0.0024	CcSEcCtD
Haloperidol—Dyspnoea—Pravastatin—atherosclerosis	0.000156	0.00239	CcSEcCtD
Haloperidol—Decreased appetite—Niacin—atherosclerosis	0.000155	0.00237	CcSEcCtD
Haloperidol—Dyspepsia—Pravastatin—atherosclerosis	0.000154	0.00236	CcSEcCtD
Haloperidol—Rash—Rosuvastatin—atherosclerosis	0.000154	0.00236	CcSEcCtD
Haloperidol—Dermatitis—Rosuvastatin—atherosclerosis	0.000154	0.00236	CcSEcCtD
Haloperidol—Urticaria—Simvastatin—atherosclerosis	0.000154	0.00236	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Niacin—atherosclerosis	0.000153	0.00235	CcSEcCtD
Haloperidol—Body temperature increased—Simvastatin—atherosclerosis	0.000153	0.00234	CcSEcCtD
Haloperidol—Headache—Rosuvastatin—atherosclerosis	0.000153	0.00234	CcSEcCtD
Haloperidol—CYP2C9—cardiovascular system—atherosclerosis	0.000153	0.0105	CbGeAlD
Haloperidol—Hypersensitivity—Lovastatin—atherosclerosis	0.000152	0.00234	CcSEcCtD
Haloperidol—Decreased appetite—Pravastatin—atherosclerosis	0.000152	0.00233	CcSEcCtD
Haloperidol—Constipation—Pravastatin—atherosclerosis	0.00015	0.00229	CcSEcCtD
Haloperidol—Hypersensitivity—Ezetimibe—atherosclerosis	0.00015	0.00229	CcSEcCtD
Haloperidol—Pruritus—Lovastatin—atherosclerosis	0.000146	0.00224	CcSEcCtD
Haloperidol—SIGMAR1—liver—atherosclerosis	0.000146	0.01	CbGeAlD
Haloperidol—Nausea—Rosuvastatin—atherosclerosis	0.000145	0.00222	CcSEcCtD
Haloperidol—HTR2A—connective tissue—atherosclerosis	0.000145	0.00994	CbGeAlD
Haloperidol—Feeling abnormal—Pravastatin—atherosclerosis	0.000144	0.00221	CcSEcCtD
Haloperidol—Pruritus—Ezetimibe—atherosclerosis	0.000144	0.0022	CcSEcCtD
Haloperidol—Hypersensitivity—Simvastatin—atherosclerosis	0.000143	0.00218	CcSEcCtD
Haloperidol—Diarrhoea—Lovastatin—atherosclerosis	0.000142	0.00217	CcSEcCtD
Haloperidol—Urticaria—Niacin—atherosclerosis	0.000141	0.00216	CcSEcCtD
Haloperidol—Body temperature increased—Niacin—atherosclerosis	0.000141	0.00215	CcSEcCtD
Haloperidol—CYP1A1—adipose tissue—atherosclerosis	0.00014	0.00962	CbGeAlD
Haloperidol—Urticaria—Pravastatin—atherosclerosis	0.000139	0.00213	CcSEcCtD
Haloperidol—Diarrhoea—Ezetimibe—atherosclerosis	0.000139	0.00213	CcSEcCtD
Haloperidol—Body temperature increased—Pravastatin—atherosclerosis	0.000138	0.00212	CcSEcCtD
Haloperidol—CYP3A5—adipose tissue—atherosclerosis	0.000137	0.00941	CbGeAlD
Haloperidol—Pruritus—Simvastatin—atherosclerosis	0.000137	0.0021	CcSEcCtD
Haloperidol—Dizziness—Lovastatin—atherosclerosis	0.000137	0.0021	CcSEcCtD
Haloperidol—Dizziness—Ezetimibe—atherosclerosis	0.000134	0.00206	CcSEcCtD
Haloperidol—HRH1—adipose tissue—atherosclerosis	0.000133	0.00913	CbGeAlD
Haloperidol—Diarrhoea—Simvastatin—atherosclerosis	0.000132	0.00203	CcSEcCtD
Haloperidol—Vomiting—Lovastatin—atherosclerosis	0.000132	0.00202	CcSEcCtD
Haloperidol—Hypersensitivity—Niacin—atherosclerosis	0.000131	0.00201	CcSEcCtD
Haloperidol—Rash—Lovastatin—atherosclerosis	0.00013	0.002	CcSEcCtD
Haloperidol—Dermatitis—Lovastatin—atherosclerosis	0.00013	0.002	CcSEcCtD
Haloperidol—Headache—Lovastatin—atherosclerosis	0.00013	0.00199	CcSEcCtD
Haloperidol—Vomiting—Ezetimibe—atherosclerosis	0.000129	0.00198	CcSEcCtD
Haloperidol—Hypersensitivity—Pravastatin—atherosclerosis	0.000129	0.00197	CcSEcCtD
Haloperidol—Dizziness—Simvastatin—atherosclerosis	0.000128	0.00196	CcSEcCtD
Haloperidol—Rash—Ezetimibe—atherosclerosis	0.000128	0.00196	CcSEcCtD
Haloperidol—Dermatitis—Ezetimibe—atherosclerosis	0.000128	0.00196	CcSEcCtD
Haloperidol—Headache—Ezetimibe—atherosclerosis	0.000127	0.00195	CcSEcCtD
Haloperidol—HTR2A—cardiovascular system—atherosclerosis	0.000126	0.00865	CbGeAlD
Haloperidol—Pruritus—Niacin—atherosclerosis	0.000126	0.00193	CcSEcCtD
Haloperidol—Pruritus—Pravastatin—atherosclerosis	0.000124	0.0019	CcSEcCtD
Haloperidol—Vomiting—Simvastatin—atherosclerosis	0.000123	0.00189	CcSEcCtD
Haloperidol—Nausea—Lovastatin—atherosclerosis	0.000123	0.00188	CcSEcCtD
Haloperidol—Rash—Simvastatin—atherosclerosis	0.000122	0.00187	CcSEcCtD
Haloperidol—CYP2C19—liver—atherosclerosis	0.000122	0.00837	CbGeAlD
Haloperidol—Dermatitis—Simvastatin—atherosclerosis	0.000122	0.00187	CcSEcCtD
Haloperidol—Diarrhoea—Niacin—atherosclerosis	0.000122	0.00186	CcSEcCtD
Haloperidol—Headache—Simvastatin—atherosclerosis	0.000121	0.00186	CcSEcCtD
Haloperidol—Nausea—Ezetimibe—atherosclerosis	0.000121	0.00185	CcSEcCtD
Haloperidol—Diarrhoea—Pravastatin—atherosclerosis	0.00012	0.00183	CcSEcCtD
Haloperidol—Dizziness—Niacin—atherosclerosis	0.000118	0.0018	CcSEcCtD
Haloperidol—Dizziness—Pravastatin—atherosclerosis	0.000116	0.00177	CcSEcCtD
Haloperidol—Nausea—Simvastatin—atherosclerosis	0.000115	0.00176	CcSEcCtD
Haloperidol—Vomiting—Niacin—atherosclerosis	0.000113	0.00173	CcSEcCtD
Haloperidol—Rash—Niacin—atherosclerosis	0.000112	0.00172	CcSEcCtD
Haloperidol—Dermatitis—Niacin—atherosclerosis	0.000112	0.00171	CcSEcCtD
Haloperidol—Headache—Niacin—atherosclerosis	0.000111	0.00171	CcSEcCtD
Haloperidol—Vomiting—Pravastatin—atherosclerosis	0.000111	0.0017	CcSEcCtD
Haloperidol—Rash—Pravastatin—atherosclerosis	0.00011	0.00169	CcSEcCtD
Haloperidol—Dermatitis—Pravastatin—atherosclerosis	0.00011	0.00169	CcSEcCtD
Haloperidol—Headache—Pravastatin—atherosclerosis	0.00011	0.00168	CcSEcCtD
Haloperidol—Nausea—Niacin—atherosclerosis	0.000106	0.00162	CcSEcCtD
Haloperidol—Nausea—Pravastatin—atherosclerosis	0.000104	0.00159	CcSEcCtD
Haloperidol—CYP1A2—liver—atherosclerosis	9.96e-05	0.00684	CbGeAlD
Haloperidol—CYP1A1—liver—atherosclerosis	9.83e-05	0.00675	CbGeAlD
Haloperidol—CYP3A5—liver—atherosclerosis	9.61e-05	0.0066	CbGeAlD
Haloperidol—CYP2C9—liver—atherosclerosis	9.46e-05	0.00649	CbGeAlD
Haloperidol—ABCB1—cardiovascular system—atherosclerosis	8.25e-05	0.00567	CbGeAlD
Haloperidol—HTR2A—liver—atherosclerosis	7.79e-05	0.00535	CbGeAlD
Haloperidol—ABCB1—adipose tissue—atherosclerosis	7.28e-05	0.005	CbGeAlD
Haloperidol—CYP3A4—liver—atherosclerosis	7.21e-05	0.00495	CbGeAlD
Haloperidol—CYP2D6—liver—atherosclerosis	7.1e-05	0.00487	CbGeAlD
Haloperidol—ABCB1—liver—atherosclerosis	5.11e-05	0.0035	CbGeAlD
Haloperidol—CYP3A4—Metabolism—LIPC—atherosclerosis	2.08e-06	3.26e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—AKT1—atherosclerosis	2.08e-06	3.25e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—NFKB1—atherosclerosis	2.08e-06	3.25e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PIK3CG—atherosclerosis	2.07e-06	3.24e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—IL6—atherosclerosis	2.07e-06	3.24e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—APOC3—atherosclerosis	2.07e-06	3.24e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PIK3CG—atherosclerosis	2.07e-06	3.24e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PIK3CG—atherosclerosis	2.07e-06	3.23e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—MMP9—atherosclerosis	2.07e-06	3.23e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—LPL—atherosclerosis	2.06e-06	3.22e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—GPX1—atherosclerosis	2.06e-06	3.22e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—LDLR—atherosclerosis	2.06e-06	3.22e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CXCL8—atherosclerosis	2.06e-06	3.21e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—NFKB1—atherosclerosis	2.04e-06	3.19e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—MAPK8—atherosclerosis	2.04e-06	3.19e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—AKT1—atherosclerosis	2.04e-06	3.18e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—APOB—atherosclerosis	2.04e-06	3.18e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CXCL8—atherosclerosis	2.03e-06	3.17e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—MAPK3—atherosclerosis	2.02e-06	3.16e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—APOB—atherosclerosis	2.02e-06	3.15e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—GPX1—atherosclerosis	2.01e-06	3.15e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CETP—atherosclerosis	2.01e-06	3.14e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—MAPK8—atherosclerosis	2.01e-06	3.14e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—CD36—atherosclerosis	2.01e-06	3.14e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—AKT1—atherosclerosis	2e-06	3.13e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PPARG—atherosclerosis	2e-06	3.12e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—INS—atherosclerosis	2e-06	3.12e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—MAPK3—atherosclerosis	1.99e-06	3.11e-05	CbGpPWpGaD
Haloperidol—DRD1—GPCR downstream signaling—AKT1—atherosclerosis	1.99e-06	3.1e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—MAPK3—atherosclerosis	1.98e-06	3.1e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—GSTM1—atherosclerosis	1.98e-06	3.1e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—MMP9—atherosclerosis	1.97e-06	3.08e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—INS—atherosclerosis	1.96e-06	3.07e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—GSTM1—atherosclerosis	1.96e-06	3.07e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CCL2—atherosclerosis	1.96e-06	3.07e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—CD36—atherosclerosis	1.96e-06	3.06e-05	CbGpPWpGaD
Haloperidol—DRD3—GPCR downstream signaling—AKT1—atherosclerosis	1.96e-06	3.06e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—INS—atherosclerosis	1.96e-06	3.06e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—INS—atherosclerosis	1.96e-06	3.06e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—IL6—atherosclerosis	1.95e-06	3.06e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PIK3CG—atherosclerosis	1.95e-06	3.05e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—NFKB1—atherosclerosis	1.95e-06	3.05e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—LPL—atherosclerosis	1.94e-06	3.04e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CCL2—atherosclerosis	1.93e-06	3.02e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—IGF1—atherosclerosis	1.93e-06	3.02e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—IL6—atherosclerosis	1.93e-06	3.02e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CCL2—atherosclerosis	1.93e-06	3.01e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—LPL—atherosclerosis	1.93e-06	3.01e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—VEGFA—atherosclerosis	1.92e-06	3.01e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—SCARB1—atherosclerosis	1.92e-06	3.01e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—MAPK8—atherosclerosis	1.92e-06	3e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—AKT1—atherosclerosis	1.91e-06	2.99e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—STAT3—atherosclerosis	1.91e-06	2.98e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—MTHFR—atherosclerosis	1.9e-06	2.97e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—IGF1—atherosclerosis	1.9e-06	2.97e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—GPX1—atherosclerosis	1.9e-06	2.96e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—IGF1—atherosclerosis	1.89e-06	2.96e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PPARG—atherosclerosis	1.89e-06	2.95e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—VEGFA—atherosclerosis	1.88e-06	2.95e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—GPX1—atherosclerosis	1.88e-06	2.94e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PPARA—atherosclerosis	1.87e-06	2.92e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—STAT3—atherosclerosis	1.87e-06	2.92e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—MMP9—atherosclerosis	1.86e-06	2.91e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—MTHFR—atherosclerosis	1.86e-06	2.9e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—VEGFA—atherosclerosis	1.85e-06	2.9e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—INS—atherosclerosis	1.85e-06	2.89e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—CD36—atherosclerosis	1.85e-06	2.89e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—NFKB1—atherosclerosis	1.84e-06	2.88e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—STAT3—atherosclerosis	1.84e-06	2.87e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—MMP9—atherosclerosis	1.83e-06	2.87e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—SERPINE1—atherosclerosis	1.83e-06	2.87e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—CD36—atherosclerosis	1.83e-06	2.86e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PPARA—atherosclerosis	1.82e-06	2.85e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—MAPK3—atherosclerosis	1.82e-06	2.85e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—HMGCR—atherosclerosis	1.82e-06	2.84e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—NFKB1—atherosclerosis	1.82e-06	2.84e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—MAPK8—atherosclerosis	1.81e-06	2.83e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—AGT—atherosclerosis	1.81e-06	2.83e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—AKT1—atherosclerosis	1.8e-06	2.82e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—SERPINE1—atherosclerosis	1.8e-06	2.82e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—HMOX1—atherosclerosis	1.8e-06	2.81e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—SERPINE1—atherosclerosis	1.8e-06	2.81e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—ALB—atherosclerosis	1.79e-06	2.81e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—MAPK8—atherosclerosis	1.78e-06	2.79e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—MAPK3—atherosclerosis	1.78e-06	2.79e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—AKT1—atherosclerosis	1.78e-06	2.78e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—APOE—atherosclerosis	1.77e-06	2.77e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—VEGFA—atherosclerosis	1.77e-06	2.77e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—TGFB1—atherosclerosis	1.77e-06	2.76e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—AGT—atherosclerosis	1.76e-06	2.76e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—CAV1—atherosclerosis	1.76e-06	2.74e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—MAPK3—atherosclerosis	1.75e-06	2.74e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—STAT3—atherosclerosis	1.75e-06	2.74e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—APOA1—atherosclerosis	1.75e-06	2.74e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—MTHFR—atherosclerosis	1.75e-06	2.74e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—NOS3—atherosclerosis	1.75e-06	2.74e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—MTHFR—atherosclerosis	1.74e-06	2.71e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—TGFB1—atherosclerosis	1.73e-06	2.7e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—APOE—atherosclerosis	1.73e-06	2.7e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—APOB—atherosclerosis	1.72e-06	2.7e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—NOS3—atherosclerosis	1.72e-06	2.69e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—NOS3—atherosclerosis	1.72e-06	2.69e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PPARA—atherosclerosis	1.72e-06	2.68e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—NOS3—atherosclerosis	1.72e-06	2.68e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—CAV1—atherosclerosis	1.71e-06	2.68e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—APOA1—atherosclerosis	1.71e-06	2.67e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—TGFB1—atherosclerosis	1.7e-06	2.66e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PPARA—atherosclerosis	1.7e-06	2.66e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—ALB—atherosclerosis	1.7e-06	2.65e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—GSTM1—atherosclerosis	1.68e-06	2.62e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—MAPK3—atherosclerosis	1.67e-06	2.62e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—VEGFA—atherosclerosis	1.67e-06	2.61e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—AGT—atherosclerosis	1.66e-06	2.6e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—STAT3—atherosclerosis	1.65e-06	2.58e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—AGT—atherosclerosis	1.65e-06	2.58e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—VEGFA—atherosclerosis	1.65e-06	2.58e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—LPL—atherosclerosis	1.65e-06	2.57e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—STAT3—atherosclerosis	1.63e-06	2.55e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—APOE—atherosclerosis	1.63e-06	2.55e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—TGFB1—atherosclerosis	1.63e-06	2.54e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—NOS3—atherosclerosis	1.62e-06	2.54e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—ABCA1—atherosclerosis	1.62e-06	2.53e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—APOE—atherosclerosis	1.62e-06	2.53e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—CAV1—atherosclerosis	1.61e-06	2.52e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—APOA1—atherosclerosis	1.61e-06	2.52e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—GPX1—atherosclerosis	1.61e-06	2.51e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—CAV1—atherosclerosis	1.6e-06	2.5e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PIK3CG—atherosclerosis	1.6e-06	2.5e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—APOA1—atherosclerosis	1.6e-06	2.5e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—MAPK3—atherosclerosis	1.58e-06	2.47e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PTGS2—atherosclerosis	1.57e-06	2.45e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CD36—atherosclerosis	1.56e-06	2.45e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PIK3CG—atherosclerosis	1.56e-06	2.44e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—MAPK3—atherosclerosis	1.56e-06	2.44e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CXCL8—atherosclerosis	1.55e-06	2.43e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PPARG—atherosclerosis	1.54e-06	2.41e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—TGFB1—atherosclerosis	1.53e-06	2.4e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CXCL8—atherosclerosis	1.53e-06	2.39e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CXCL8—atherosclerosis	1.52e-06	2.38e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—INS—atherosclerosis	1.51e-06	2.37e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—TGFB1—atherosclerosis	1.51e-06	2.36e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PPARG—atherosclerosis	1.51e-06	2.35e-05	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—AKT1—atherosclerosis	1.5e-06	2.34e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PTGS2—atherosclerosis	1.48e-06	2.32e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—MTHFR—atherosclerosis	1.48e-06	2.32e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—INS—atherosclerosis	1.48e-06	2.31e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—IL6—atherosclerosis	1.48e-06	2.31e-05	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—AKT1—atherosclerosis	1.48e-06	2.31e-05	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—AKT1—atherosclerosis	1.47e-06	2.3e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PIK3CG—atherosclerosis	1.47e-06	2.3e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PIK3CG—atherosclerosis	1.46e-06	2.28e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PPARA—atherosclerosis	1.45e-06	2.27e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—IL6—atherosclerosis	1.45e-06	2.27e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—IL6—atherosclerosis	1.45e-06	2.27e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PPARG—atherosclerosis	1.42e-06	2.22e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—AGT—atherosclerosis	1.41e-06	2.2e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PPARG—atherosclerosis	1.41e-06	2.2e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MMP9—atherosclerosis	1.4e-06	2.19e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—INS—atherosclerosis	1.39e-06	2.18e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—HMOX1—atherosclerosis	1.39e-06	2.17e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—NFKB1—atherosclerosis	1.39e-06	2.17e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—ALB—atherosclerosis	1.39e-06	2.17e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MMP9—atherosclerosis	1.38e-06	2.16e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—APOE—atherosclerosis	1.38e-06	2.16e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—INS—atherosclerosis	1.38e-06	2.16e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MMP9—atherosclerosis	1.38e-06	2.15e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CAV1—atherosclerosis	1.37e-06	2.14e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—NFKB1—atherosclerosis	1.37e-06	2.14e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MAPK8—atherosclerosis	1.37e-06	2.13e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—APOA1—atherosclerosis	1.36e-06	2.13e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—NFKB1—atherosclerosis	1.36e-06	2.13e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—AKT1—atherosclerosis	1.36e-06	2.13e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—ALB—atherosclerosis	1.35e-06	2.12e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MAPK8—atherosclerosis	1.34e-06	2.1e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MAPK8—atherosclerosis	1.34e-06	2.1e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—AKT1—atherosclerosis	1.34e-06	2.09e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—AKT1—atherosclerosis	1.34e-06	2.09e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—IL6—atherosclerosis	1.33e-06	2.08e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—APOB—atherosclerosis	1.33e-06	2.08e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—NOS3—atherosclerosis	1.33e-06	2.07e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—IL6—atherosclerosis	1.3e-06	2.04e-05	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—AKT1—atherosclerosis	1.3e-06	2.03e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—NOS3—atherosclerosis	1.3e-06	2.02e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GSTM1—atherosclerosis	1.29e-06	2.02e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—IL6—atherosclerosis	1.28e-06	2.01e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—ALB—atherosclerosis	1.28e-06	1.99e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—LPL—atherosclerosis	1.27e-06	1.99e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—ALB—atherosclerosis	1.27e-06	1.98e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—VEGFA—atherosclerosis	1.26e-06	1.97e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—STAT3—atherosclerosis	1.25e-06	1.95e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PIK3CG—atherosclerosis	1.25e-06	1.95e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—VEGFA—atherosclerosis	1.24e-06	1.94e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GPX1—atherosclerosis	1.24e-06	1.94e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—VEGFA—atherosclerosis	1.24e-06	1.93e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—AKT1—atherosclerosis	1.23e-06	1.92e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—STAT3—atherosclerosis	1.23e-06	1.92e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—STAT3—atherosclerosis	1.23e-06	1.92e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—IL6—atherosclerosis	1.22e-06	1.91e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—NOS3—atherosclerosis	1.22e-06	1.91e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PTGS2—atherosclerosis	1.21e-06	1.9e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—NOS3—atherosclerosis	1.21e-06	1.89e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CD36—atherosclerosis	1.21e-06	1.89e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—AKT1—atherosclerosis	1.2e-06	1.88e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PPARG—atherosclerosis	1.2e-06	1.88e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MAPK3—atherosclerosis	1.19e-06	1.86e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PTGS2—atherosclerosis	1.18e-06	1.85e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—AKT1—atherosclerosis	1.18e-06	1.85e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—INS—atherosclerosis	1.18e-06	1.84e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MAPK3—atherosclerosis	1.17e-06	1.83e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MAPK3—atherosclerosis	1.17e-06	1.83e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—TGFB1—atherosclerosis	1.16e-06	1.81e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—IL6—atherosclerosis	1.15e-06	1.81e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—MTHFR—atherosclerosis	1.14e-06	1.79e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—IL6—atherosclerosis	1.14e-06	1.78e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—TGFB1—atherosclerosis	1.14e-06	1.78e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—TGFB1—atherosclerosis	1.14e-06	1.78e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—AKT1—atherosclerosis	1.13e-06	1.77e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PPARA—atherosclerosis	1.12e-06	1.75e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PTGS2—atherosclerosis	1.12e-06	1.75e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PTGS2—atherosclerosis	1.11e-06	1.73e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—AKT1—atherosclerosis	1.09e-06	1.71e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—AGT—atherosclerosis	1.09e-06	1.7e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—ALB—atherosclerosis	1.08e-06	1.69e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—AKT1—atherosclerosis	1.07e-06	1.67e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—APOE—atherosclerosis	1.07e-06	1.67e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CAV1—atherosclerosis	1.06e-06	1.65e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—APOA1—atherosclerosis	1.05e-06	1.65e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—AKT1—atherosclerosis	1.05e-06	1.64e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—NOS3—atherosclerosis	1.03e-06	1.62e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PIK3CG—atherosclerosis	9.61e-07	1.5e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PTGS2—atherosclerosis	9.46e-07	1.48e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PPARG—atherosclerosis	9.28e-07	1.45e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—INS—atherosclerosis	9.1e-07	1.42e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—IL6—atherosclerosis	8.72e-07	1.36e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—IL6—atherosclerosis	8.58e-07	1.34e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—IL6—atherosclerosis	8.56e-07	1.34e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—ALB—atherosclerosis	8.34e-07	1.3e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—AKT1—atherosclerosis	8.04e-07	1.26e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—NOS3—atherosclerosis	7.98e-07	1.25e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—AKT1—atherosclerosis	7.91e-07	1.24e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—AKT1—atherosclerosis	7.9e-07	1.23e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—AKT1—atherosclerosis	7.89e-07	1.23e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—AKT1—atherosclerosis	7.46e-07	1.17e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PTGS2—atherosclerosis	7.3e-07	1.14e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—AKT1—atherosclerosis	6.1e-07	9.54e-06	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—AKT1—atherosclerosis	5.95e-07	9.31e-06	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—AKT1—atherosclerosis	5.61e-07	8.77e-06	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—AKT1—atherosclerosis	5.56e-07	8.7e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—AKT1—atherosclerosis	4.75e-07	7.43e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—AKT1—atherosclerosis	3.67e-07	5.73e-06	CbGpPWpGaD
